SLC5A2 and metabolic syndrome: The EASE trials for empagliflozin [74], the DEPICT program for dapagliflozin [77], and the inTandem program investigating the double inhibitor treatment of SGLT1 and SGLT2, sotagliflozin [82] have provided evidence for improved glycemic control, reduced insulin doses, and modifying features of the metabolic syndrome (weight and blood pressure).